Theratechnologies Inc. (THTX)
USD 2.78
(2.96%)
USD 2.78
(2.96%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 81.76 Million USD | 2.13% |
| 2022 | 80.05 Million USD | 14.66% |
| 2021 | 69.82 Million USD | 5.71% |
| 2020 | 66.05 Million USD | 4.49% |
| 2019 | 63.21 Million USD | 43.49% |
| 2018 | 44.05 Million USD | 32.59% |
| 2017 | 33.22 Million USD | 20.36% |
| 2016 | 27.6 Million USD | 22.41% |
| 2015 | 22.54 Million USD | 282.22% |
| 2014 | 5.89 Million USD | -17.27% |
| 2013 | 7.13 Million USD | -47.78% |
| 2012 | 13.65 Million USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 22.01 Million USD | 36.83% |
| 2024 Q1 | 16.08 Million USD | -31.41% |
| 2024 Q3 | 22.6 Million USD | 2.68% |
| 2023 Q1 | 19.9 Million USD | -7.06% |
| 2023 Q4 | 23.45 Million USD | 12.45% |
| 2023 Q2 | 17.54 Million USD | -11.85% |
| 2023 FY | 81.76 Million USD | 2.13% |
| 2023 Q3 | 20.85 Million USD | 18.84% |
| 2022 Q4 | 21.42 Million USD | 2.93% |
| 2022 Q2 | 19.26 Million USD | 3.83% |
| 2022 FY | 80.05 Million USD | 14.66% |
| 2022 Q1 | 18.55 Million USD | -1.05% |
| 2022 Q3 | 20.81 Million USD | 8.01% |
| 2021 Q1 | 15.43 Million USD | -19.31% |
| 2021 Q3 | 17.85 Million USD | 0.37% |
| 2021 FY | 69.82 Million USD | 5.71% |
| 2021 Q2 | 17.78 Million USD | 15.28% |
| 2021 Q4 | 18.75 Million USD | 5.05% |
| 2020 Q3 | 14.04 Million USD | -18.14% |
| 2020 FY | 66.05 Million USD | 4.49% |
| 2020 Q1 | 15.71 Million USD | -4.15% |
| 2020 Q2 | 17.16 Million USD | 9.18% |
| 2020 Q4 | 19.12 Million USD | 36.12% |
| 2019 Q2 | 15.6 Million USD | 3.4% |
| 2019 Q4 | 16.39 Million USD | 1.79% |
| 2019 FY | 63.21 Million USD | 43.49% |
| 2019 Q1 | 15.09 Million USD | 7.96% |
| 2019 Q3 | 16.11 Million USD | 3.22% |
| 2018 Q3 | 13.52 Million USD | 40.89% |
| 2018 Q2 | 9.59 Million USD | 18.3% |
| 2018 Q1 | 8.11 Million USD | -16.9% |
| 2018 FY | 44.05 Million USD | 32.59% |
| 2018 Q4 | 13.98 Million USD | 3.4% |
| 2017 Q4 | 9.76 Million USD | 8.69% |
| 2017 Q2 | 7.41 Million USD | 9.0% |
| 2017 Q1 | 6.8 Million USD | -11.96% |
| 2017 FY | 33.22 Million USD | 20.36% |
| 2017 Q3 | 8.98 Million USD | 21.14% |
| 2016 Q3 | 6.8 Million USD | -1.27% |
| 2016 Q2 | 6.89 Million USD | 6.68% |
| 2016 Q4 | 7.72 Million USD | 13.55% |
| 2016 Q1 | 6.46 Million USD | -4.43% |
| 2016 FY | 27.6 Million USD | 22.41% |
| 2015 FY | 22.54 Million USD | 282.22% |
| 2015 Q4 | 6.76 Million USD | -2.49% |
| 2015 Q1 | 3.65 Million USD | 56.54% |
| 2015 Q3 | 6.93 Million USD | 19.06% |
| 2015 Q2 | 5.82 Million USD | 59.42% |
| 2014 Q1 | 1.5 Million USD | 28.23% |
| 2014 Q2 | 2.2 Million USD | 46.08% |
| 2014 Q3 | 3684.26 USD | -99.83% |
| 2014 Q4 | 2.33 Million USD | 63244.46% |
| 2014 FY | 5.89 Million USD | -17.27% |
| 2013 Q3 | 2.06 Million USD | -8.43% |
| 2013 Q2 | 2.25 Million USD | 28.82% |
| 2013 FY | 7.13 Million USD | -47.78% |
| 2013 Q1 | 1.74 Million USD | -55.43% |
| 2013 Q4 | 1.17 Million USD | -42.99% |
| 2012 Q1 | 3.2 Million USD | -13.58% |
| 2012 Q4 | 3.92 Million USD | 1.98% |
| 2012 Q2 | 2.57 Million USD | -19.67% |
| 2012 Q3 | 3.84 Million USD | 49.32% |
| 2012 FY | 13.65 Million USD | 0.0% |
| 2011 Q2 | 3.56 Million USD | -0.88% |
| 2011 Q4 | 3.71 Million USD | 3.34% |
| 2011 Q1 | 3.59 Million USD | -86.37% |
| 2011 Q3 | 3.59 Million USD | 0.76% |
| 2010 Q3 | 1.61 Million USD | -0.5% |
| 2010 Q2 | 1.62 Million USD | -0.38% |
| 2010 Q1 | 1.63 Million USD | -23.48% |
| 2010 Q4 | 26.4 Million USD | 1530.45% |
| 2009 Q3 | 11.5 Million USD | 630.38% |
| 2009 Q1 | 1.12 Million USD | 411.92% |
| 2009 Q2 | 1.57 Million USD | 39.65% |
| 2009 Q4 | 2.13 Million USD | -81.44% |
| 2008 Q3 | 99.78 Thousand USD | 1884.28% |
| 2008 Q1 | 5101.52 USD | -99.63% |
| 2008 Q2 | 5028.66 USD | -1.43% |
| 2008 Q4 | 220.33 Thousand USD | 120.82% |
| 2007 Q2 | 748.01 Thousand USD | 205.06% |
| 2007 Q3 | 708.13 Thousand USD | -5.33% |
| 2007 Q1 | 245.2 Thousand USD | -13.91% |
| 2007 Q4 | 1.39 Million USD | 96.36% |
| 2006 Q3 | 372.71 Thousand USD | 10159.45% |
| 2006 Q1 | 417.45 Thousand USD | -17.09% |
| 2006 Q2 | 3632.90 USD | -99.13% |
| 2006 Q4 | 284.82 Thousand USD | -23.58% |
| 2005 Q1 | 12.23 Million USD | 1953.06% |
| 2005 Q3 | 344.34 Thousand USD | -31.52% |
| 2005 Q4 | 503.52 Thousand USD | 46.23% |
| 2005 Q2 | 502.84 Thousand USD | -95.89% |
| 2004 Q3 | 445.65 Thousand USD | -22.36% |
| 2004 Q1 | 583.82 Thousand USD | -30.53% |
| 2004 Q2 | 573.98 Thousand USD | -1.69% |
| 2004 Q4 | 596.15 Thousand USD | 33.77% |
| 2003 Q3 | 679.76 Thousand USD | -9.24% |
| 2003 Q4 | 840.38 Thousand USD | 23.63% |
| 2003 Q2 | 748.99 Thousand USD | -2.51% |
| 2003 Q1 | 768.24 Thousand USD | 2.29% |
| 2002 Q4 | 751.02 Thousand USD | -15.25% |
| 2002 Q1 | - USD | -100.0% |
| 2002 Q2 | 939.71 Thousand USD | 0.0% |
| 2002 Q3 | 886.16 Thousand USD | -5.7% |
| 2001 Q1 | 217.36 Thousand USD | 244.56% |
| 2001 Q4 | 2.6 Million USD | 404242.84% |
| 2001 Q3 | 645.30 USD | -98.16% |
| 2001 Q2 | 35.12 Thousand USD | -83.84% |
| 2000 Q1 | 344.57 Thousand USD | 59.73% |
| 2000 Q2 | 200.22 Thousand USD | -41.89% |
| 2000 Q3 | 148.69 Thousand USD | -25.74% |
| 2000 Q4 | 63.08 Thousand USD | -57.57% |
| 1999 Q4 | 215.73 Thousand USD | -35.52% |
| 1999 Q3 | 334.54 Thousand USD | 64.43% |
| 1999 Q1 | 132.58 Thousand USD | -60.6% |
| 1999 Q2 | 203.46 Thousand USD | 53.46% |
| 1998 Q3 | 126.55 Thousand USD | -38.56% |
| 1998 Q4 | 336.49 Thousand USD | 165.9% |
| 1998 Q1 | 70.26 Thousand USD | -48.75% |
| 1998 Q2 | 205.95 Thousand USD | 193.12% |
| 1997 Q1 | 73.06 Thousand USD | 0.0% |
| 1997 Q4 | 137.1 Thousand USD | 90.44% |
| 1997 Q2 | 145.11 Thousand USD | 98.61% |
| 1997 Q3 | 71.99 Thousand USD | -50.39% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Intra-Cellular Therapies, Inc. | 464.37 Million USD | 82.392% |
| PainReform Ltd. | - USD | -Infinity% |
| Alvotech | 91.43 Million USD | 10.576% |
| Collegium Pharmaceutical, Inc. | 566.76 Million USD | 85.574% |
| ANI Pharmaceuticals, Inc. | 486.81 Million USD | 83.204% |
| Aquestive Therapeutics, Inc. | 50.58 Million USD | -61.643% |
| Journey Medical Corporation | 79.18 Million USD | -3.262% |
| Dynavax Technologies Corporation | 232.28 Million USD | 64.8% |
| Esperion Therapeutics, Inc. | 116.33 Million USD | 29.716% |
| Bright Green Corporation | 401.49 Thousand USD | -20265.089% |
| Pacira BioSciences, Inc. | 674.97 Million USD | 87.886% |
| Embecta Corp. | 1.12 Billion USD | 92.705% |
| Sunshine Biopharma, Inc. | 24.09 Million USD | -239.371% |
| Sunshine Biopharma, Inc. | 24.09 Million USD | -239.371% |
| SCYNEXIS, Inc. | 140.14 Million USD | 41.656% |
| Petros Pharmaceuticals, Inc. | 5.82 Million USD | -1304.304% |
| Silver Spike Investment Corp. | 11.72 Million USD | -597.518% |
| China SXT Pharmaceuticals, Inc. | 1.92 Million USD | -4139.778% |
| Alpha Teknova, Inc. | 36.68 Million USD | -122.887% |
| Safety Shot Inc | 202.67 Thousand USD | -40243.415% |
| Procaps Group, S.A. | 409.92 Million USD | 80.054% |
| Cosmos Health Inc. | 53.37 Million USD | -53.182% |
| Harrow Health, Inc. | 130.19 Million USD | 37.198% |
| Sonoma Pharmaceuticals, Inc. | 12.73 Million USD | -542.042% |
| Biofrontera Inc. | 34.07 Million USD | -139.981% |
| DURECT Corporation | 8.54 Million USD | -856.528% |
| Supernus Pharmaceuticals, Inc. | 607.52 Million USD | 86.541% |
| Cronos Group Inc. | 88.84 Million USD | 7.966% |
| OptiNose, Inc. | 70.98 Million USD | -15.182% |
| Ironwood Pharmaceuticals, Inc. | 442.73 Million USD | 81.532% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| RedHill Biopharma Ltd. | 6.51 Million USD | -1155.364% |
| Organogenesis Holdings Inc. | 433.14 Million USD | 81.123% |
| Guardion Health Sciences, Inc. | 12.24 Million USD | -567.54% |
| Cumberland Pharmaceuticals Inc. | 39.55 Million USD | -106.723% |
| Radius Health, Inc. | 2.88 Billion USD | 97.163% |
| Universe Pharmaceuticals INC | 32.3 Million USD | -153.071% |
| ProPhase Labs, Inc. | 44.38 Million USD | -84.22% |
| Phibro Animal Health Corporation | 1.01 Billion USD | 91.966% |
| Procaps Group S.A. | 409.92 Million USD | 80.054% |
| TherapeuticsMD, Inc. | 1.3 Million USD | -6179.877% |
| Viatris Inc. | 15.42 Billion USD | 99.47% |
| Rockwell Medical, Inc. | 83.61 Million USD | 2.21% |
| Aytu BioPharma, Inc. | 81 Million USD | -0.941% |
| SIGA Technologies, Inc. | 139.91 Million USD | 41.563% |
| Tilray Brands, Inc. | 788.94 Million USD | 89.636% |
| Lifecore Biomedical, Inc. | 128.26 Million USD | 36.252% |
| Shineco, Inc. | 9.8 Million USD | -734.169% |
| PetIQ, Inc. | 1.1 Billion USD | 92.58% |
| Regencell Bioscience Holdings Limited | - USD | -Infinity% |
| Incannex Healthcare Limited | 12 Thousand USD | -681266.667% |
| Neurocrine Biosciences, Inc. | 1.88 Billion USD | 95.667% |
| Alimera Sciences, Inc. | 80.75 Million USD | -1.251% |
| Assertio Holdings, Inc. | 152.06 Million USD | 46.232% |
| Shuttle Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Clever Leaves Holdings Inc. | 17.41 Million USD | -369.449% |
| Cyclo Therapeutics, Inc. | 1.07 Million USD | -7496.026% |
| Avadel Pharmaceuticals plc | 27.96 Million USD | -192.401% |
| Hempacco Co., Inc. | 4.04 Million USD | -1921.041% |
| Talphera, Inc. | 651 Thousand USD | -12459.754% |
| Alvotech | 91.43 Million USD | 10.576% |
| Eagle Pharmaceuticals, Inc. | 316.61 Million USD | 74.175% |
| Lantheus Holdings, Inc. | 1.29 Billion USD | 93.693% |
| Currenc Group, Inc. | 53.25 Million USD | -53.532% |
| Kamada Ltd. | 144.75 Million USD | 43.517% |
| Indivior PLC | 1.09 Billion USD | 92.519% |
| Evoke Pharma, Inc. | 5.18 Million USD | -1478.264% |
| Flora Growth Corp. | 76.07 Million USD | -7.484% |
| Cyclo Therapeutics, Inc. | 1.07 Million USD | -7496.026% |
| Evolus, Inc. | 202.08 Million USD | 59.54% |
| HUTCHMED (China) Limited | 837.99 Million USD | 90.243% |
| Amphastar Pharmaceuticals, Inc. | 644.39 Million USD | 87.312% |
| Akanda Corp. | 2.16 Million USD | -3685.279% |